FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914895037> ?p ?o ?g. }

• W2914895037 abstract "Interleukin-21 (IL-21), a member of the common cytokine receptor γ chain (γc) family, is secreted by CD4+ T cells and natural killer T cells and induces effector function through interactions with the IL-21 receptor (IL-21R)/γc complex expressed on both immune and non-immune cells. Numerous studies suggest that IL-21 plays a significant role in autoimmune disorders. Therapeutic intervention to disrupt the IL-21/IL-21R/γc interaction and inhibit subsequent downstream signal transduction could offer a treatment paradigm for these diseases. Potent neutralizing antibodies reported in the literature were generated after extensive immunizations with human IL-21 alone and in combination with various adjuvants. To circumvent the laborious method of antibody generation while targeting a conserved functional epitope, we designed a novel alternating-antigen immunization strategy utilizing both human and cynomolgus monkey (cyno) IL-21. Despite the high degree of homology between human and cyno IL-21, our alternating-immunization strategy elicited higher antibody titers and more potent neutralizing hybridomas in mice than did the immunization with human IL-21 antigen alone. The lead hybridoma clone was humanized by grafting the murine complementarity-determining regions onto human germline framework templates, using a unique rational design. The final humanized and engineered antibody, MEDI7169, encodes only one murine residue at the variable heavy/light-chain interface, retains the sub-picomolar affinity for IL-21, specifically inhibits IL-21/IL-21R-mediated signaling events and is currently under clinical development as a potential therapeutic agent for autoimmune diseases. This study provides experimental evidence of the immune system's potential to recognize and respond to shared epitopes of antigens from distinct species, and presents a generally applicable, novel method for the rapid generation of exceptional therapeutic antibodies using the hybridoma platform." @default.
• W2914895037 created "2019-02-21" @default.
• W2914895037 creator A5004692206 @default.
• W2914895037 creator A5012364063 @default.
• W2914895037 creator A5018504567 @default.
• W2914895037 creator A5021741157 @default.
• W2914895037 creator A5025626111 @default.
• W2914895037 creator A5051881041 @default.
• W2914895037 creator A5064642149 @default.
• W2914895037 creator A5068466390 @default.
• W2914895037 creator A5081491801 @default.
• W2914895037 creator A5081649942 @default.
• W2914895037 creator A5085976480 @default.
• W2914895037 creator A5088256361 @default.
• W2914895037 creator A5088889060 @default.
• W2914895037 date "2019-01-25" @default.
• W2914895037 modified "2023-10-18" @default.
• W2914895037 title "Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategy" @default.
• W2914895037 cites W1515836930 @default.
• W2914895037 cites W1561925924 @default.
• W2914895037 cites W1619199643 @default.
• W2914895037 cites W1939229836 @default.
• W2914895037 cites W1966167232 @default.
• W2914895037 cites W1969134054 @default.
• W2914895037 cites W1971793099 @default.
• W2914895037 cites W1977333753 @default.
• W2914895037 cites W1982679430 @default.
• W2914895037 cites W1987213198 @default.
• W2914895037 cites W1989053318 @default.
• W2914895037 cites W1989198317 @default.
• W2914895037 cites W1992204954 @default.
• W2914895037 cites W1995297089 @default.
• W2914895037 cites W2009322401 @default.
• W2914895037 cites W2009573319 @default.
• W2914895037 cites W2010905675 @default.
• W2914895037 cites W2024956060 @default.
• W2914895037 cites W2026623158 @default.
• W2914895037 cites W2030085576 @default.
• W2914895037 cites W2034236426 @default.
• W2914895037 cites W2039269176 @default.
• W2914895037 cites W2044791218 @default.
• W2914895037 cites W2050105922 @default.
• W2914895037 cites W2055889057 @default.
• W2914895037 cites W2058055013 @default.
• W2914895037 cites W2064912737 @default.
• W2914895037 cites W2065669145 @default.
• W2914895037 cites W2068182901 @default.
• W2914895037 cites W2070486601 @default.
• W2914895037 cites W2074534136 @default.
• W2914895037 cites W2074572906 @default.
• W2914895037 cites W2077025291 @default.
• W2914895037 cites W2088139849 @default.
• W2914895037 cites W2136130231 @default.
• W2914895037 cites W2139237097 @default.
• W2914895037 cites W2140649712 @default.
• W2914895037 cites W2152716989 @default.
• W2914895037 cites W2153329352 @default.
• W2914895037 cites W2154912830 @default.
• W2914895037 cites W2155238510 @default.
• W2914895037 cites W2161132784 @default.
• W2914895037 cites W2163433134 @default.
• W2914895037 cites W2163828646 @default.
• W2914895037 cites W2165470016 @default.
• W2914895037 cites W2167018634 @default.
• W2914895037 cites W2239052723 @default.
• W2914895037 cites W2474760928 @default.
• W2914895037 cites W2515956381 @default.
• W2914895037 cites W2614699145 @default.
• W2914895037 cites W2749679400 @default.
• W2914895037 cites W33415804 @default.
• W2914895037 cites W91258909 @default.
• W2914895037 doi "https://doi.org/10.1371/journal.pone.0211236" @default.
• W2914895037 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6347146" @default.
• W2914895037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30682117" @default.
• W2914895037 hasPublicationYear "2019" @default.
• W2914895037 type Work @default.
• W2914895037 sameAs 2914895037 @default.
• W2914895037 citedByCount "4" @default.
• W2914895037 countsByYear W29148950372020 @default.
• W2914895037 countsByYear W29148950372021 @default.
• W2914895037 crossrefType "journal-article" @default.
• W2914895037 hasAuthorship W2914895037A5004692206 @default.
• W2914895037 hasAuthorship W2914895037A5012364063 @default.
• W2914895037 hasAuthorship W2914895037A5018504567 @default.
• W2914895037 hasAuthorship W2914895037A5021741157 @default.
• W2914895037 hasAuthorship W2914895037A5025626111 @default.
• W2914895037 hasAuthorship W2914895037A5051881041 @default.
• W2914895037 hasAuthorship W2914895037A5064642149 @default.
• W2914895037 hasAuthorship W2914895037A5068466390 @default.
• W2914895037 hasAuthorship W2914895037A5081491801 @default.
• W2914895037 hasAuthorship W2914895037A5081649942 @default.
• W2914895037 hasAuthorship W2914895037A5085976480 @default.
• W2914895037 hasAuthorship W2914895037A5088256361 @default.
• W2914895037 hasAuthorship W2914895037A5088889060 @default.
• W2914895037 hasBestOaLocation W29148950371 @default.
• W2914895037 hasConcept C147483822 @default.
• W2914895037 hasConcept C159654299 @default.
• W2914895037 hasConcept C195616568 @default.
• W2914895037 hasConcept C203014093 @default.
• W2914895037 hasConcept C2780801004 @default.

• next